Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD<sup>+</sup> acute myeloid leukemia cells.

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD⁺ acute myeloid leukemia cells.

Liu, Yi; Wei, Jing; Liu, Jiaxin; Ma, Weina; Duan, Yanting; Liu, Daihong.

Afiliación

Liu Y; Department of Hematology, Chinese PLA Medical School, Beijing 100853, P.R. China.
Wei J; Department of Hematology, The Sixth Medical Center of PLA General Hospital, Beijing 100048, P.R. China.
Liu J; Department of Hematology, The Sixth Medical Center of PLA General Hospital, Beijing 100048, P.R. China.
Ma W; Department of Hematology, The Sixth Medical Center of PLA General Hospital, Beijing 100048, P.R. China.
Duan Y; Department of Hematology, The Sixth Medical Center of PLA General Hospital, Beijing 100048, P.R. China.
Liu D; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, P.R. China.

Oncol Lett ; 21(5): 397, 2021 May.

Article en En | MEDLINE | ID: mdl-33777220

Palabras clave

AXL receptor tyrosine kinase small-molecule inhibitor; FLT3 mutations; acute myeloid leukemia; anti-AXL receptor tyrosine kinase antibody; drug resistance; synergistic cytotoxic effect